Triple-negative breast cancer (TNBC) is a molecularly heterogeneous subtype of breast cancer, and responses to standard neoadjuvant chemoimmunotherapy are variable. While multiple prognostic biomarkers have been identified in TNBC, we currently lack predictive biomarkers for response to specific therapies. The development of robust validated biomarkers could enable biology-adapted administration of specific cytotoxic agents and potentially selective administration of immunotherapy, thereby enabling personalized systemic therapy.

In this webinar,  Shane Stecklein of the Kansas University Medical Center will discuss, how using Almac claraT they have identified the DNA damage immune response (DDIR) gene expression signature as prognostic in a cohort of TNBC patients enrolled on the SWOG S9313 adjuvant chemotherapy trial. We have also shown that DDIR, in combination with homologous recombination deficiency (HRD), can identify immune-enriched and immune-depleted prognostic groups that have unique immune microenvironmental features that may reflect variable vulnerabilities to chemoimmunotherapy.

WHAT WILL ATTENDEES LEARN:

• Despite many reported prognostic biomarkers in TNBC, we lack predictive biomarkers to guide individualized therapy.
• DDIR and HRD reflect partially overlapping but independent prognostic biomarkers in TNBC.
• DDIR/HRD classification enables therapeutic vulnerability-based classification of TNBC and may be able to identify rational approaches for individualized chemoimmunotherapy.
• How Almac clara^T can aid cancer researchers in novel biomarker discovery.

SPEAKERS:

 Dr Shane Stecklein, Assistant Professor of Radiation Oncology

Dr Gemma Logan, CDx Programme Manager, Almac Diagnostic Services